多发性骨髓瘤的预后与分层策略  

Prognosis and stratification strategies of multiple myeioma

作　　者：杜辰星 李增军[1] 邱录贵[1] 

机构地区：[1]中国医学科学院北京协和医学院血液病医院(血液学研究所),天津300020

出　　处：《国际输血及血液学杂志》2017年第2期113-119,共7页International Journal of Blood Transfusion and Hematology

基　　金：国家自然科学基金重点项目（81630007）;国家自然科学基金面上项目（81570181）

摘　　要：多发性骨髓瘤（MM）是一种高度异质性的浆细胞恶性肿瘤。染色体高度不稳定及复杂的遗传学异常为MM细胞的生物学特征，亦为最重要的预后因素。在发病初期，MM细胞发生奇数染色体三体或免疫球蛋白（Ig）H基因重排，逐步积累基因片段的扩增或缺失，获得恶性的增殖力、侵袭力及耐药性，导致MM患者预后不佳。笔者拟就MM的临床、遗传学、影像学等多方面对其预后指标进行介绍，分析现有分层系统的优势与不足，并探讨合理的预后分层策略。Multiple myeloma （MM） is a highly heterogeneous plasma cell malignant disorder. Regarded as specific biological features of MM, chromosome instability and cytogenetic abnormality are the strongest indicators of impaired survival. At early stage of MM, tumor cells usually undergo odd chromosome trisomies or immunoglobulin fig） H translocations, and pile up secondary gene amplifications and deletions, evolving into a more proliferative, invasive, and drug-resistant stage. And MM patients have poor prognosis. The author will summarize various prognostic markers from clinical, genetic and imagiological aspects, analyze the advantages and disadvantages of current staging systems, and discuss the reasonable stratification strategy.

关 键 词：多发性骨髓瘤 预后 细胞遗传学 肿瘤分期 

分 类 号：R733.3[医药卫生—肿瘤]